Gene Knockout Cell Line Construction Service Key Players and Development Strategy

Gene Knockout Cell Line Construction Service Market Companies

• GenScript
• Thermo Fisher Scientific
• Horizon Discovery/PerkinElmer
• Charles River Laboratories
• WuXi AppTec
• Synthego
• VectorBuilder
• Cellecta
• EditCo
• Creative Biogene/Creative Bioarray
• Cyagen Biosciences
• Ubigene
• BPS Bioscience
• ABM
• Origene Technologies
• GenOway/in-vivo & in-vitro model specialists
• Takara Bio
• Eurofins/specialized functional genomics CROs
• Agilent
• Smaller specialist labs & boutique CROs

Market Growth

The global gene knockout cell line construction market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the hundreds of millions over the forecast years from 2025 to 2034. This surge is attributed to evolving consumer preferences and technological advancements reshaping the industry.

Drifts in the Gene Knockout Cell Line Construction Service Market

• The growing R&D investment in gene editing approaches and widespread applications of the gene knockout method are widely impacting the overall market expansion.
• In August 2025, Asimov, a synthetic biology company, made a cell line development partnership with Ottimo Pharma, a biopharmaceutical company evolving PD1/VEGFR2 dual pathway antibodies to extend the lives of people living with cancer.
• In July 2025, Pluristyx, a leading provider of induced pluripotent stem cell (iPSC) technologies and proprietary gene editing solutions, completed its most recent round of investment led by BioLife Solutions to expand its product portfolio and commercial operations.
• In March 2025, Arbor Biotechnologies, a biotechnology company, secured a $73.9 million Series C financing to accelerate the advancement of its pipeline of innovative gene editing therapeutics targeting diseases in the liver and central nervous system (CNS).

Latest Announcements by Industry Leaders

• In May 2025, ProBioGen announced an agreement with Polpharma Biologics, an international biotech company devoted to the development and manufacture of biosimilars. Dr. Volker Sandig, Chief Scientific Officer at ProBioGen, commented that this will offer a best-in-class expression platform that ensures efficiency, expression stability, and superior quality.
• In May 2025, Trailhead Biosystems Inc., a biotechnology company, announced it had secured $20 million in financing. Jan Jensen, Ph.D., CEO/CSO and founder of Trailhead Biosystems, replied that this will enable them to further advance how iPSCs are differentiated into precise human cell types for both drug discovery and therapeutic development.

Recent Developments in the Gene Knockout Cell Line Construction Service Market

• In August 2025, WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), launched WuXia293Stable, a new platform created for the development and manufacturing of innovative, difficult-to-express molecules.
• In February 2025, Cellistic, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing services, unveiled its Allo Chassis, a ready-to-use, immune-cloaked iPSC cell line derived from CD34+ and CD4+ T-cell primary cells.
• In December 2024, Beckman Coulter Life Sciences, a global player in laboratory automation and innovation, and a company of Danaher Corporation, launched the Cydem VT Automated Clone Screening System.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com